Critical Six-Month Window Predicts Relapse Risk After ECT in Schizophrenia

Can the Six-Month Window Predict Relapse in Schizophrenia?

Relapse After Acute Electroconvulsive Therapy for Schizophrenia: First Meta-Analysis Reveals Critical Six-Month Window

The effectiveness of electroconvulsive therapy (ECT) for treatment-resistant schizophrenia has been established in numerous studies, but questions have lingered about its long-term benefits. Now, a groundbreaking systematic review and meta-analysis provides the first comprehensive look at relapse rates following acute ECT treatment for schizophrenia, revealing a critical six-month window during which patients are most vulnerable to symptom recurrence. The study, which analyzed data from 29 studies involving 3,876 patients, found that approximately 40% of patients relapse within six months after completing acute ECT, with relapse rates continuing to climb to 55% by the two-year mark.

Electroconvulsive therapy has long been recognized as an effective intervention for treatment-resistant depression and catatonia, and has demonstrated short-term efficacy for schizophrenia patients who fail to respond adequately to multiple antipsychotic medications. Previous reviews have confirmed that acute ECT can achieve short-term improvements in psychiatric symptoms for up to six weeks, reduce relapse and rehospitalization risk, and facilitate earlier hospital discharge. However, until now, evidence regarding medium- to long-term outcomes has been insufficient, contributing to significant variations in clinical guidelines for ECT use in schizophrenia across different regions. In Asia, ECT is widely used for schizophrenia, whereas Western countries have been more hesitant to recommend it proactively.

How Was the Meta-Analysis Conducted?

The researchers conducted an extensive search of multiple databases, including Embase, PubMed, Web of Science, and the Cochrane Library, identifying both randomized controlled trials and observational studies published through March 2024. The analysis revealed that relapse after acute ECT was observed in 24% of patients within the first three months, increased to approximately 40% after six months, and plateaued somewhat thereafter, reaching approximately 55% after two years. These findings suggest that the first six months following acute ECT represent a critical period for intervention to prevent relapse, with the highest risk occurring within the initial three months.

Perhaps the most clinically significant finding emerged from the subgroup analysis examining maintenance therapy strategies. Patients who received maintenance therapy with antipsychotics alone had relapse rates of 33%, 47%, 47%, and 51% at 3, 6, 12, and 24 months, respectively. In contrast, patients who received a combination of antipsychotics and continuation/maintenance ECT (C/M-ECT) showed consistently lower relapse rates of 12%, 20%, 30%, and 40% at the same time points. This substantial difference suggests that the benefits of acute ECT may be better sustained through the combined maintenance approach, particularly during the critical early months when relapse risk is highest.

The pattern of relapse following acute ECT for schizophrenia bears striking similarities to findings in depression studies, where relapse rates of approximately 25% at 3 months, 40% at 6 months, and 50% at 2 years have been observed. However, in recent years, robust evidence has emerged for strategies to prolong treatment response and suppress relapse in depression, including combined use of pharmacotherapy with C/M-ECT. The current findings suggest similar approaches may benefit patients with schizophrenia, though the evidence base remains less developed.

Regional differences in ECT utilization were apparent in the study sample, with the vast majority of participants (86.46%) recruited from Asian countries, compared to much smaller proportions from North America (6.76%), Europe (5.65%), and Oceania (1.19%). This asymmetry reflects the previously noted regional differences in clinical guidelines and practice, with Asian countries more readily adopting ECT for schizophrenia treatment.

Of the 3,811 individuals whose sex was indicated in the included studies, 1,818 (47.7%) were female and 1,993 (52.3%) were male. The mean age of participants was 38.1 years, with a mean disease duration of 9.5 years. The severity of illness at baseline was substantial, with mean Brief Psychiatric Rating Scale scores of 51.7 and Positive and Negative Syndrome Scale scores of 110.4, indicating significant symptomatology prior to ECT treatment. These demographic characteristics help contextualize the study population as individuals with chronic, severe schizophrenia who had likely failed multiple prior treatment attempts.

The study methodology was robust, employing a double arcsine square root transformation to normalize sampling distribution and stabilize variance, particularly important given the small sample sizes in some included studies. The researchers used DerSimonian Laird random effects models to account for variation between studies and increase the generalizability of conclusions. Between-study heterogeneity was explored using τ² and I² statistics, with a prediction interval approach to reinforce evaluations of heterogeneity.

The risk of bias assessment revealed that 13.8% of studies had a high risk of bias, 48.3% had moderate risk, and 37.9% had low risk. Randomized controlled trials consistently demonstrated low bias risks, whereas observational studies varied considerably. This variability in methodological quality underscores the need for caution when interpreting the pooled results, though the consistency of findings across studies with different designs provides some reassurance regarding the validity of the overall conclusions.

What Limitations Affect the Study's Findings?

Despite its comprehensive approach, the study had several limitations. High heterogeneity was observed across studies at all time points, suggesting significant variations in study parameters, populations, and treatment variables. Many included studies had small sample sizes, reflecting the challenges inherent in ECT research and the selective nature of the population requiring ECT for severe schizophrenia. Additionally, the studies employed different diagnostic criteria, definitions of relapse, and recruitment criteria, potentially affecting the interpretation of results. The meta-analysis was also unable to separate the impact of concurrent medication from ECT on outcome events due to the retrospective nature of much of the included data.

How Might These Findings Change Clinical Practice?

The findings have important implications for clinical practice, suggesting that strategies to prevent relapse should be implemented immediately following successful acute ECT treatment. The apparent advantage of combined maintenance therapy with antipsychotics and C/M-ECT warrants further investigation through high-quality studies. Future research should focus on multicenter trials with standardized definitions of relapse, detailed information on clinical assessments, ECT settings, and pharmacotherapy in both acute and maintenance phases, as well as exploration of the neurobiological mechanisms underlying post-ECT relapse and relapse prevention.

Could these findings shift the approach to maintenance therapy following acute ECT for schizophrenia in regions where ECT is less frequently utilized? Might standardized protocols for combined maintenance therapy with antipsychotics and C/M-ECT become more widely adopted based on this evidence? How can clinicians best identify which patients are most likely to benefit from combined maintenance approaches versus those who might remain stable with antipsychotics alone? What specific ECT parameters and schedules might optimize outcomes in the maintenance phase? These questions represent important areas for future research and clinical consideration as the field continues to refine approaches to managing treatment-resistant schizophrenia.

This meta-analysis represents a significant contribution to the understanding of long-term outcomes following ECT in schizophrenia, providing clinicians with valuable information to guide treatment planning and maintenance strategies for this challenging patient population. The identification of the six-month post-treatment window as a period of particular vulnerability may help focus clinical attention and resources during this critical time, potentially improving long-term outcomes for patients with treatment-resistant schizophrenia.

Summary

A comprehensive systematic review and meta-analysis examining 29 studies with 3,876 patients has identified a critical six-month window following acute electroconvulsive therapy (ECT) for schizophrenia during which patients face the highest risk of relapse. The research found that approximately 40% of patients experience symptom recurrence within six months after completing acute ECT treatment, with relapse rates rising to 55% by two years. The most significant finding emerged from subgroup analysis, which revealed that patients receiving combined maintenance therapy with antipsychotics and continuation/maintenance ECT showed substantially lower relapse rates compared to those receiving antipsychotics alone—20% versus 47% at six months. The study population consisted of patients with chronic, severe schizophrenia who had failed multiple prior treatments, with a mean age of 38.1 years and mean disease duration of 9.5 years. Regional differences were notable, with 86.46% of participants recruited from Asian countries, reflecting variations in clinical practice and guidelines between regions. The findings suggest that the first six months following acute ECT represent a critical period requiring intensive intervention to prevent relapse, with the highest risk occurring within the initial three months. These results have important implications for clinical practice, indicating that strategies to prevent relapse should be implemented immediately following successful acute ECT treatment, and that combined maintenance approaches may offer superior outcomes compared to pharmacotherapy alone.